Pharma's Obesity Campaigns Juggle Awareness And Advertising

(MENAFN- Swissinfo) Pharma giants are bankrolling obesity awareness campaigns globally. In an analysis, Swissinfo examines thorny questions about whether drug advertising bans are still enforceable – or even relevant. Select your language

Generated with artificial intelligence. Listening: Pharma's obesity campaigns juggle awareness and advertising This content was published on June 4, 2026 - 10:20 8 minutes

I report on the Swiss pharmaceutical industry and healthcare topics such as access to medicine, biomedical innovation, and the impact of diseases like cancer. I grew up just outside San Francisco and studied international affairs with a focus on development economics and healthcare policy. Prior to joining SWI swissinfo in 2018, I was a freelance journalist and a researcher on business and human rights.

More from this aut English Departm

. Pharmaceutical firms such as Eli Lilly are running obesity awareness campaigns in countries including Switzerland.

. Regulators are investigating if these campaigns breach bans on advertising prescription-only medicines to the public.

. Swissmedic has launched an investigation, while France has fined both Eli Lilly and drugmaker Novo Nordisk for indirect promotion.

Summary generated by AI

In early March, a digital billboard in the train station at Zurich airport caught my eye. It consisted of just a few words on a light green-blue screen:“Adipositas ist nicht Ihre Schuld” (obesity is not your fault) along with a website link, a QR code and a call to consult your doctor. A couple of seconds later, a slide in red appeared with the logo of the US firm Eli Lilly, one of the two major makers of obesity treatments.

Over the next month my colleague spotted similar billboards in the French-speaking part of Switzerland, some of which were found next to ads for McDonald's. Company-sponsored posters, TV commercials and online campaigns on obesity have appeared in other countries from France to India.

It's pretty unusual to see pharmaceutical company logos on advertising billboards in Switzerland. Here, as in almost every other high-income country aside from the US and New Zealand, advertisements for prescription-only medicine to the public are banned.

Having seen many drug commercials in the US in my life, I know how annoying and harmful they can be. StudiesExternal link in the US show that while drug ads can make patients aware of new treatments, they can also drive demand for expensive brands and lead to overprescription.

The billboards found in Switzerland, which were part of a month-long campaign Eli Lilly ran around World Obesity Day on March 4, aren't like the in-your-face ads you see in the US though. They don't mention any specific product or show anyone using an injection pen, taking a pill or spouting the miracle results of any prescription drug.

The websiteExternal link referred to on the billboard mentions medication along with other weight-management strategies but doesn't reference Eli Lilly's own drugs.

In an email to Swissinfo, the company wrote the“non-promotional, science-based educational activities are designed to increase awareness of a disease, its burden, and the importance of seeking appropriate medical assistance”.

When awareness becomes advertising

Companies are allowedExternal link to sponsor disease awareness campaigns in Switzerland, Japan and many other countries in the world if they are complete, balanced and objective. This means that they can refer to prescription-only medicine as long as they mention all the other prevention and treatment approaches out there and the positive and negative aspects objectively.

Article 2 of the OrdinanceExternal link on Advertising for Medicinal Products defines advertising as“all information, marketing and incentive measures aimed at promoting the prescription, dispensing, sale, consumption or use of medicinal products”. This applies to all print, television and electronic media.

If a company doesn't mention any prescription medicine, it could still be in violation of the rules if it indirectly references a prescription-only medicine. This is where things get tricky.

“It's a very fine line between raising awareness of diseases, which has a positive aspect, and advertising for prescription-only medicines,” said Celine Weber, a lawyer in the life sciences team at law firm Walder Wyss in Zurich.“Nowadays it's very hard not to have an indirect reference to a medicine, especially when you are one of the only companies, if not the only company, offering a medicine for a specific condition.”

For transparency reasons companies put their logo or name on any campaign they sponsor. But simply mentioning a company name or using brand colours and graphic elements in connection with a specific disease can often constitute an unauthorised indirect reference to a particular product, said a spokesperson for Swissmedic, which is responsible for enforcing advertising rules for therapeutic products.

Regulators are starting to take a closer look at these campaigns. Swissmedic has launched an investigation into Eli Lilly's obesity campaign to see if they are in breach of the advertising ban. Last year Spain's ministry of health investigated an obesity awareness campaign by Danish drugmaker Novo Nordisk to determine if it constituted indirect advertising for prescription-only medicine.

More More Medicine access Swiss regulator and media clash over weight-loss drugs

This content was published on Jan 21, 2025 Swissmedic has taken legal action against media for alleged unauthorised advertising of weight-loss drugs. Swiss media say this is censorship.

Read more: Swiss regulator and media clash over weight-loss

MENAFN04062026000210011054ID1111213111